Santa Monica-based Kite Pharma announced March 5 that the Food and Drug Administration has granted accelerated approval for the company’s principal drug, Yescarta, for the treatment of adult patients ...
Kite, a Gilead Company, today announced the U.S. Food and Drug Administration has granted approval for Tecartus ® for the treatment of adult patients with relapsed or refractory B-cell precursor acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback